Home Sulfos 2-(4-(4,9-Diethoxy-1-oxo-1H-benzo[f]isoindol-2(3H)-yl)phenyl)-N-(phenylsulfonyl)acetamide

2-(4-(4,9-Diethoxy-1-oxo-1H-benzo[f]isoindol-2(3H)-yl)phenyl)-N-(phenylsulfonyl)acetamide

CAS No.:
439288-66-1
Catalog Number:
AG00DAAO
Molecular Formula:
C30H28N2O6S
Molecular Weight:
544.6181
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%
1 week
United States
$140
- +
10mg
99%
1 week
United States
$182
- +
25mg
99%
1 week
United States
$265
- +
50mg
99%
1 week
United States
$404
- +
100mg
99%
1 week
United States
$682
- +
Product Description
Catalog Number:
AG00DAAO
Chemical Name:
2-(4-(4,9-Diethoxy-1-oxo-1H-benzo[f]isoindol-2(3H)-yl)phenyl)-N-(phenylsulfonyl)acetamide
CAS Number:
439288-66-1
Molecular Formula:
C30H28N2O6S
Molecular Weight:
544.6181
IUPAC Name:
N-(benzenesulfonyl)-2-[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)phenyl]acetamide
InChI:
InChI=1S/C30H28N2O6S/c1-3-37-28-23-12-8-9-13-24(23)29(38-4-2)27-25(28)19-32(30(27)34)21-16-14-20(15-17-21)18-26(33)31-39(35,36)22-10-6-5-7-11-22/h5-17H,3-4,18-19H2,1-2H3,(H,31,33)
InChI Key:
XREWXJVMYAXCJV-UHFFFAOYSA-N
SMILES:
CCOc1c2C(=O)N(Cc2c(c2c1cccc2)OCC)c1ccc(cc1)CC(=O)NS(=O)(=O)c1ccccc1
UNII:
A9P1ZGY0SE
Properties
Complexity:
953  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
544.167g/mol
Formal Charge:
0
Heavy Atom Count:
39  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
544.622g/mol
Monoisotopic Mass:
544.167g/mol
Rotatable Bond Count:
9  
Topological Polar Surface Area:
110A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.8  
Literature
Title Journal
EP4 receptor stimulation down-regulates human eosinophil function. Cellular and molecular life sciences : CMLS 20111101
The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Investigative ophthalmology & visual science 20110601
Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts. British journal of pharmacology 20110601
Effect of PGE2 on DA tone by EP4 modulating Kv channels with different oxygen tension between preterm and term. International journal of cardiology 20110217
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer 20100601
Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. American journal of respiratory and critical care medicine 20091115
EP4 and EP2 receptor subtypes involved in colonic secretion in rat. Basic & clinical pharmacology & toxicology 20080901
Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. British journal of pharmacology 20080501
Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. Journal of experimental therapeutics & oncology 20080101
Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. British journal of pharmacology 20071101
Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study. American journal of physiology. Endocrinology and metabolism 20071101
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. British journal of pharmacology 20060601
Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. British journal of pharmacology 20050201
Properties